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ABSTRACT
Electronic cigarette or vaping use associated lung injury (EVALI) is a pulmonary
disease among those who vaped illicit tetrahydrocannabinol (THC) cartridges that resulted in
hospitalization or death. Vitamin E acetate (VEA) was a common additive present in the
bronchioalveolar lavage fluid (BALF) of patients who were hospitalized with EVALI.
However, little is known about pulmonary exposure to vitamin E acetate (VEA) when
inhaled through vaping. The hypothesis of this study is the cytotoxicity of vaped VEA is due,
at least in part, to the pyrolytic breakdown products of VEA produced by vaping, as opposed
to VEA itself. From this study, VEA was not found to exhibit cytotoxicity on THP-1 human
monocytic cells; however, vaped VEA showed toxicity. Multiple VEA byproducts, and
VEA, were observed by spectrophotometric, HPLC, GCMS, LCMS, and LCMS/MS
analysis. A peak with a molecular weight of 390 remained consistent in all vaped VEA
collections.
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CHAPTER 1: INTRODUCTION
VAPING AND ELECTRONIC CIGARETTES
As of 2020, the electronic cigarette (E-cigarettes) vaping industry is estimated to be
worth 15.04 billion USD and is expected to expand by 28.1% from 2021-202824. Ecigarettes, also known as electronic nicotine delivery systems (ENDS) or vaping devices,
have become the preferred tobacco use product among youth since 2014 19. Vaping devices
come in a variety of shapes and sizes with all of them containing a heating element, battery,
and a chamber to hold vaping liquid. The use of an e-cigarette is known as “vaping” because
the liquids used in e-cigarettes are aerosolized through the heating element, known as an
atomizer, for inhalation. E-cigarette liquids can be complex and heterogenous, containing
various thickening agents and flavorings such as coconut oil, medium-chain triglycerides
(MCT), propylene glycol (PG), vegetable glycerin (VG), and linoleic acid. Various
components mentioned above, such as PG and VG, have been found to exhibit cytotoxicity.
The goal of this study is to further characterize the cytotoxicity of vaping liquids specifically
those involved in illicit tetrahydrocannabinol (THC) cartridges containing vitamin E acetate
(VEA).
Many young adults believe that using e-cigarettes are safer than smoking traditional
cigarettes and, while this may have some validity due to traditional cigarettes containing over
7000 chemicals per inhalation within their smolder, that does not imply that e-cigarette
aerosols are harmless20. E-cigarettes are most commonly used to inhale nicotine, the
addictive component of tobacco products. However, recently with the rise in and legalization
of recreational marijuana, e-cigarette devices have gained in popularity for those wanting to
vape the psychoactive component of marijuana, THC. In 2014, among adults who reported
1

using marijuana, 9.9% reported using e-cigarettes as their preferred method for THC
consumption and 75% of college students reported using THC within their e-cigarettes17,18.
Vaping marijuana has continued to rise, as the most recent data revealed an increase to 14%
in 201941. It should be noted with the increased use of recreational marijuana, there are still
states in which marijuana is not legalized for recreational use, leading to the illicit use of
THC. Although in 2016 all e-cigarettes were to be regulated by the FDA for tobacco
consumption, the same cannot be said for THC cartridges, allowing for the possibility of
novel, untested chemicals to be incorporated into products. Some of the agents found within
e-cigarette liquids are considered safe when taken orally; however, intake through the lungs
is untested for safety. Furthermore, when heated during vaping, e-cigarette liquids may
break down to toxic byproducts. Studies have shown that e-cigarette use is hazardous as
some of the flavorings and diluents are toxic to the respiratory tract 3,4,12.

TOXICITY COMPONENTS OF VAPING LIQUIDS AND HEALTH IMPLICATIONS OF
VAPING
Many studies have investigated the use of e-cigarettes and the health implications that
vaping can have on an individual. Various studies have found that two primary ingredients
used in e-cigarettes, PG and VG, are cytotoxic to cells and can contribute to a lipoid
pneumonia3,4,12,22. Diacetyl is a buttery flavoring agent that has been commonly used within
vaping liquids, which has shown cytotoxic properties resulting in pathological inflammation
leading to fibrosis of the bronchioles and irreversible lung damage and causing a limitation of
airflow within the lungs21,26. Not only can vaping lead to irreversible lung damage, but
various components of vaping liquids can be carcinogenic. Because vaping requires thermal
energy to aerosolize vaping liquids, there is the possibility for thermal degradation of various
2

chemicals. For example, toxic products of vaping liquids include carbonyls such as
formaldehyde, acrolein, and acetaldehyde; these aldehydes are known to contribute to
cardiovascular diseases and both cancerous and noncancerous pulmonary diseases 14,15,23.
Because carcinogenic compounds are present within vaping liquids, thermal degradation may
increase their concentration and expose an individual to higher concentrations per inhalation.
Other toxic components of vaping are found in the aerosol from secondhand exposure
as an e-cigarette user exhales. The secondhand aerosol that someone may inhale can contain
ultrafine particles, smaller than 1 µm in diameter, volatile organic compounds, such as
benzene, and heavy metals like nickel, tin, and lead25. The multitude of toxic components
from vaping are not completely known and the examples mentioned above are just a few that
have been identified for their toxicity. Further studies are needed to characterize the
multitude of potential toxic components found within vaping liquids and their link to various
types of lung injury.

WHAT IS EVALI?
Recently, a disease known as “Electronic cigarettes or vaping use-associated lung
injury” (EVALI) broke out in the US with a total of 2,807 hospitalizations and 68 deaths as
of February 20201. EVALI is a form of acute lung injury with varying pathological findings,
such as acute fibrinous pneumonitis, pneumonia, and diffuse alveolar damage19. The
histopathological findings consistent with EVALI include acute eosinophilic pneumonia,
lipoid pneumonia, and respiratory-bronchiolitis interstitial lung disease22,30,31. There are no
specific histologic findings except for the formation of foamy macrophages and pneumocyte
vacuolization42. EVALI occurred among people who vaped illicit THC cartridges containing
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vitamin E acetate (VEA)2. VEA has limited toxicity when taken orally, but little is known
about VEA when vaped. Not only was VEA found in illicit THC cartridges, but
bronchoalveolar lavage fluid (BALF) samples also revealed the presence of VEA in patients
who experienced EVALI in 48 of the 51 patients that were hospitilized2. As mentioned, many
thickening and flavoring agents are used for ENDS vaping liquids, and the same can be said
for THC vaping liquids. Typically, THC vaping liquids contain a mixture of terpenes,
cannabinoids, flavoring additives and various solvents to manipulate the viscosity and
volume of the mixture 27. Because THC is a lipophilic molecule, THC requires the use of a
lipophilic agent for proper miscibility as the common humectants of PG and VG are polar
and two separate layers are formed when trying to blend the two compounds. Because of the
lipophilicity of VEA and its ability to be aerosolized, VEA makes an optimal humectant to be
added to THC cartridges for vaping. However, VEA has not been tested or used in
commercially available THC cartridges. Further studies are needed to understand how vaping
can break down VEA through oxidation and thermal degradation reactions leading to the
production of toxic byproducts and, the potential role that vaping VEA may have in EVALI.

A.

B.

Figure 1. A) Chest x-ray of a patient with EVALI showing bilateral patchy opacities
representing dense material accumulation inside the cavity of the lung. B) Image of a healthy
lung filled with air represented by the black space and visible costophrenic angles from
Belok et al. (2020)36.

4

VITAMIN E ACETATE
VEA can be purchased over the counter at many stores as an oral supplement and is
often found within cosmetic products such as skin creams. VEA lipophilic characteristics can
be attributed to its molecular structure, which contains a substituted chromanol ring and an
acetate functional group that prevents oxidation. VEA also has a phytol chain containing
three chiral centers (Fig. 2A) and thus can form eight stereoisomers. At the cellular level,
vitamin E (VE) acts as an antioxidant that scavenges reactive oxygen species (ROS). As VE
is oxidized to form tocopherylquinone (TQ), a reduction reaction would produce the
antioxidant tocopheryl-hydroquinone (THQ). Reduction of VE in a single electron oxidation
state in the cellular setting may occur through a reduction reaction involving ascorbic acid.
As VE is regenerated, ascorbic acid forms a ROS that can be reduced by glutathione40.
Because of VEA’s unique molecular structure and mechanism of action, further studies are
warranted to observe potential byproducts formed from VEA when both oxidation and
pyrolysis are introduced.

BYPRODUCTS OF VITAMIN E ACETATE
As mentioned previously, VEA has the potential to be oxidized into TQ through an
oxidation reaction. When VEA undergoes a 2-electron oxidation reaction within cells, it
leads to the formation of TQ5 (Fig. 2B). Quinones may be chemically reactive molecules that
can further undergo redox cycling, leading to the formation of ROS that may lead to DNA
damage, cellular oxidative stress, and cell death5. However, studies have shown that the
toxicity of quinones is dependent on the substitutions around the chromanol ring. For
example, Wang et al. (2006) reported a significant decrease in cell viability when comparing
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g-TQ to a-TQ, with g-TQ, which has fewer methyl substitutions than a-TQ, having a
significant impact on viability. The toxicity of g-TQ was attributed to the difference in the
substitution of the chromanol ring compared to a-TQ, allowing for g-TQ to undergo Michael
addition reactions due to one unsubstituted carbon5.
Importantly, few studies have looked into how vaping may alter the breakdown of
VEA. However, some of the various breakdown byproducts that have been reported from
vaping VEA are acetone, 3,7,11-trimethyl-1-dodecanol, 1-pristene, various quinone
structures such as durohydroquinone, durohydroquinone monoacetate, methyl octadecenoate,
and ketene formed from the release of the acetate group on VEA through vaping 3,6,7,10,11. The
formation of ketene has been reported as a toxic byproduct of VEA in vaping, as a study
reported by Wu Dan et al. (2020), showing the release of ketene when VEA was vaped using
cone voltages from five to thirty eV7. Ketene itself is a highly reactive molecule that is
quickly consumed upon its formation28. Because of ketenes’ extreme reactivity, the general
public may rarely come into contact with this colorless gas. There have been reports on
ketenes exhibiting high pulmonary toxicity at high concentrations and minor irritation, along
with central nervous system impairment at lower concentrations, in mouse models32,33. Of
note, based on the vaping temperatures of e-cigarettes, quinone formation is more
energetically favorable compared to the formation of ketene (Fig.3 A and B)6. Recently,
Matsumoto et al. (2020) reported the toxicity of vaped VEA is dose-dependent, based on
their cell culture model, using human AT II cells as they saw a decrease in viability with
increased exposure to vaped VEA9. Matsumoto et al. (2020) also showed an accumulation of
water within the lungs of mice exposed to vaped VEA and an increase in lipid-laden
macrophages and neutrophilic inflammation. Although various byproducts have been
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reported from vaping VEA, and other studies have shown the cytotoxicity of vaped VEA
alone, no studies have characterized a specific byproduct from vaped VEA responsible for
cytotoxicity. Thus, we hypothesize the cytotoxicity of vaped VEA is due, at least in part, to
the pyrolytic breakdown products of VEA produced by vaping, as opposed to VEA itself. The
mechanistic hypothesis for my specific aims are as follows 1) VEA alone will exhibit little to
no cytotoxicity, 2) vaping VEA will result in the formation of multiple byproducts, 3)
characterization of a cytotoxic byproduct from vaped VEA will demonstrate unique
byproducts. It is important to consider how oxidation can play a role in the degradation of
VEA and how the introduction of pyrolysis through vaping must be thoroughly investigated
to verify the formation of other potentially cytotoxic byproducts. Ultimately, vaping VEA
may form multiple cytotoxic byproducts with the potential to cause or contribute to EVALI.

A.

B.

Figure 2. A) Molecular structure of VEA showing the chromanol ring, phytol chain and
acetate group (image provided from PubChem).10,11 B) Molecular structure of atocopherylquinone the oxidized form of VEA (image from PubChem)34,35.
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A.

B.
Figure 3. A) Theoretical breakdown products of chromanol ring of VEA based on energy
requirements for the formation of ketene. B) Theoretical breakdown products of a chromanol
ring and the energy requirements for the formation of a quinone. (From Narimani et al.,
2020)6.
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Figure 4. E-cigarette exposure platform set up in the laboratory of Dr. Matthew Campen
(UNM, Department of Pharmaceutical Sciences).

TOXICITY ASSAYS
Many assays that can be used to measure cytotoxicity in cell cultures. One of the
older methods used to measure cell viability and proliferation is through the use of a
hemocytometer, which is a counting chamber device for quantifying and characterizing cells.
Found within the counting area of the hemocytometer are nine 1x1mm squares. These
squares are then further dived into three directions of 0.25x0.25mm, 0.25x0.20mm and
0.20x0.20mm. The central square of the grid is divided into a 0.05x0.05mm squares37. By
thoroughly mixing the cell culture sample and counting the cells within a given area of the
hemocytometer grid, the concentration of cells can be determined from the sample.
Combining a hemocytometer with trypan blue allows for the determination of cell viability in
a given sample. Viability is measurable with trypan blue through the mechanism of action in
which trypan blue works. Trypan blue is an azo dye that is unable to penetrate through intact
9

cell membranes of viable cells. As a cell’s membrane becomes compromised, trypan blue is
able to enter a cell and dye the cells blue, marking them as dead39. Another assay used to
measure cytotoxicity indirectly is the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay, a colorimetric assay that assesses metabolic cellular activity38. The
MTT assay requires the use of tetrazolium dye that can be reduced via oxidoreductase
enzymes of the cell to formazan. Following an incubation period and the addition of a
solubilizing reagent, a colorimetric change is visible within wells containing metabolically
active cells. Advantages of the MTT assay are that it is relatively simple and allows for the
analysis of many samples in a short period of time. Unlike the trypan blue and
hemocytometry assay, the MTT assay does not provide a true measurement of proliferation
or viability. Aside from the MTT assay not measuring cell viability and proliferation directly,
there are other shortcomings with the assay, such as various compounds may alter the
metabolic activity of oxidoreductase enzymes leading to inaccurate results. Thus, validation
of MTT assay results may be necessary.
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CHAPTER 2: MATERIALS AND METHODS
CHEMICALS
DL-a-tocopherol acetate, (±)-a-tocopherol, a-tocopherylquinone, astemizole, and
Pure Ethanol were purchased from Millipore Sigma (St. Louis, MO). Stock solutions of DLa-tocopherol acetate, (±)-a-tocopherol, a-tocopherylquinone, were prepared using 100%
(v/v) ethanol. Stock solutions of astemizole were prepared using 100% ethanol. MEM Amino
Acids solution (50x), Trypan blue solution (0.4%) were purchased from Millipore Sigma.
Methanol and water used were HPLC grade.

CELL LINES
THP-1 human monocyte cells were maintained in RPMI-1640 with 10% (v/v) fetal
bovine serum, 1% (w/v) penicillin and streptomycin, and 1% (w/v) glutamine.

PREPARATION OF VARIOUS TREATMENT GROUPS
To prepare various treatments of a-tocopherylquinone, DL-a-tocopherol acetate, and
(±)-a-tocopherol, the desired mass was calculated using the molecular weight of each
chemical, and using the desired volume, i.e., 1mL. For these studies, 5mM and 10mM stock
solutions were prepared of each chemical and from these chemical stock dilutions further
dilutions were conducted to achieve the desired µM, i.e., 10µM, 15µM, 20µM, 25µM,
35µM, and 45µM concentration using 100% ethanol as the diluent. Prior to administration of
the various chemicals to the cells, 135µL of albumin was added to a 15mL (Corning
Incorporated, Corning, NY 14831) centrifuge tube when only using one chemical per
treatment. Once the albumin and chemicals are added together, they were mixed for 30
11

seconds by vortex. For co-treatment experiments requiring two chemicals i.e. 10µM of TQ
and 25µM of VEA the volume of albumin was doubled to 270µL and, mixed for 30 seconds
by vortex. Lastly, cell culture media (RPMI-1640) was added to each treatment group to
bring the final volume to 3mL, followed by mixing for another 30 seconds via vortex.
Chemical treatments were prepared at a 2X concentration to account for 1:2 dilution (1mL of
treatment and 1mL of cells in the wells) when administering treatments to cells.
DOSE RESPONSE OF THP-1 CELLS TO α-TOCOPHERYLQUINONE, DL-αTOCOPHEROL ACETATE, AND (±)-α-TOCOPHEROL
THP-1 cells were plated in a 12-well polystyrene cell culture plate (Corning
Incorporated, Corning, NY 14831) at 1.27x104 cells/well by gently pipetting 1mL of cells
into each well. Then, with prepared solutions of various chemicals (e.g., DL-a-tocopherol
acetate, (±)-a-tocopherol, a-tocopherylquinone) and following the steps mentioned above to
ensure a 2x concentration (50µM) for each treatment that was made prior to administration to
the cells. Each well of cells received 1mL of treatment, which equates to a 25µM
concentration per treatment. Analysis of this dose-response is described below in the cell
growth and viability analysis section. This experiment was carried out for 6 days.

DOSE RESPONSE OF THP-1 CELLS TO VARIOUS CONCENTRATIONS OF αTOCOPHERYLQUINONE
THP-1 cells were plated in a 12-well polystyrene cell culture plate (Corning
Incorporated, Corning, NY 14831) at 2.5x104 cells/well by gently pipetting 1mL of cells into
each well. With prepared stock solutions of a-tocopherylquinone (10mM and 5mM), cells
were treated with 10µM, 17.5µM, and 25µM following the steps stated above; all were
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prepared at a 2x concentration. This experiment was carried out over 5 days with analysis of
this experiment described below.

CO-TREATMENT OF THP-1 CELLS WITH α-TOCOPHERYLQUINONE, DL-αTOCOPHEROL ACETATE, AND (±)-α-TOCOPHEROL IN A 12-WELL PLATE
DOSE RESPONSE OF THP-1 CELLS IN A 96-WELL PLATE TO DL-α-TOCOPHEROL
ACETATE
THP-1 Cells were plated in a 96-well polystyrene cell culture plate (Corning
Incorporated, Corning, NY 14831) at 5x103 cells/well using 50µL per well. Once cells were
plated treatment with DL-a-tocopherol acetate was added at 10µM, 15µM, 20µM, 25µM,
35µM, and 45µM, along with a VC (which contained 135µL of albumin and 13.5µL of
ethanol) and untreated control. Analysis of this plate was done at 2 days post treatment.
Analysis of cell growth and viability are described below.

DOSE RESPONSE OF THP-1 CELLS EXPOSED TO VAPED DL-α-TOCOPHEROL
ACETATE
THP-1 cells were plated in a 96-well polystyrene cell culture plate (Corning
Incorporated, Corning, NY 14831) at 3.75x103 cells/well using 50µL per well a total of four
plates were made. Once cells were plated they were treated with various concentrations of
vaped DL-a-tocopherol acetate i.e. 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, VC, and
untreated controls. All treatment groups, except untreated control, received 135µL of
albumin. Analysis with MTT assay is described below. The various time points that were
used for analysis were days one through four after treatment.
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DOSE RESPONSE OF DIFFERENTIATED THP-1 CELLS WITH VAPED DL-αTOCOPHEROL ACETATE
Following the THP-1 cell differentiation methods mentioned below, THP-1 cells
were plated at 5x103 cells/well using 50µL per well. The cells were treated with 0.05%,
0.1%, 0.2%, 0.3%, 0.4%, and 0.5% (all treatments used 135µL of albumin) vaped DL-atocopherol acetate and, using the MTT analysis described below, an analysis was done 2 days
post-treatment.

CELL GROWTH AND VIABILITY ANALYSIS
In order to assess cell growth and viability, two methods were used. First, was
through a trypan blue exclusion assay using a hemocytometer. When performing a dose
response in the 12-well plates, which had a total volume of 2mL, various time points were
chosen to do the analysis, i.e., one day after treatment and up to six days post-treatment. On
each day of the analysis, the cells were thoroughly mixed by pipetting gently with a 5mL
Pasteur Pipette per treatment group. Once the cells were thoroughly mixed, 300µL aliquots
were taken from each well and placed in separate 75mL sterile tubes representing one for
each individual sample. Then, using a 96 well plate, 10.5µL of trypan blue were added to an
empty well of the 96 well plate and 50µL of cells were added to the well with the 50µL of
trypan blue. From the well containing both cells and trypan blue, 10.5µL was drawn up and
placed on each side of the hemocytometer. Cell counts were carried out using the inner
quadrant of the hemocytometer and, taking the average of the two counts for cells stained
blue, they were counted as nonviable. Cells that were not stained blue were counted as
viable.
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For a 96-well plate, cell growth and viability were analyzed using an (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay from Millipore Sigma
(St. Louis, MO). THP-1 cells and A549 cells were plated at 3.0x104 cells/well per 50µL and
then treated with various concentrations of vaped DL-a-tocopherol acetate. It is important to
leave one column blank and only treat with MTT and solubilizing reagent to subtract this
value from treatment groups. At the time points of one day through four days post treatment,
cells were analyzed using the MTT assay. For preparation of the MTT assay, cells were
treated with 10µL MTT reagent and placed in the incubator for four hours. After four hours
of incubation, cells were then treated with 100µL of solubilization reagent and placed in the
incubator overnight. After incubating overnight, the cells were placed on an orbital shaker set
to 500 rpm for five minutes before analysis on a Spectramax iD5 (Molecular Devices San
Jose, CA) plate reader using a 600nm wavelength.

VAPING COLLECTION
The custom-built vaping apparatus set-up in Dr. Matthew Campen’s laboratory
(UNM, Dept. Pharmaceutical Sciences) allows for a vaping device to be secured in place
while being activated with a linear actuator at predetermined time points. Vaped DL-atocopherol acetate was collected by filling the holding chamber of a SMOK G-Priv 3 mod
with 3mL of DL-a-tocopherol acetate, ensuring that the atomizer (TFV16 Dual Mesh 0.15W
coil) was primed thoroughly using a syringe to saturate the cotton of the atomizer. Once the
atomizer and holding chamber were assembled onto the vaping device, the operating
conditions were set to vaporize the material at 30 watts/inhalation. The actuator settings were
set to 2-second inhalations with a 1-minute interval between the next strike. Rubber tubing
15

was used to form a tight seal around the mouth piece of the vaping device, which was tightly
connected to a 1mL Costar Stripette (Corning Incorporate, NY). The stripette was inserted
through a size 1 cork attached to a borosilicate glass cell culture tube filled with 10mL of
100% (v/v) ethanol. The ethanol was bubbled with a stone percolator to increase the surface
area of the vaped DL-a-tocopherol acetate within the ethanol. Another 1mL Costar Stripette
(Corning Incorporate, NY) was also inserted through the cork to attach another rubber tube
for a vacuum to siphon off the vaped material. DL-a-tocopherol acetate was aerosolized in
this manner for over one hour and stored at room temperature in foil while being corked and
sealed off with parafilm and stored in a refrigerator until analysis.

ANALYSIS OF VAPED VEA MATERIAL VIA SPECTROPHOTOMETER
For analyzing the vaped VEA material, several techniques were used starting with a
spectrophotometric analysis. This analysis was initiated by blanking the DU800
spectrophotometer (Thermo Fisher, Madison, WI) with 1mL of 100% ethanol (v/v) (Millipore
Sigma St. Louis, MO) placed in quartz cuvette graciously lent to us from Dr. Pam Hall’s
laboratory. Once blanked, an initial scan was performed using the 1mL of ethanol to have a
zero line appear on the graph. Next, using known concentrations of DL-a-tocopherol acetate,
(±)-a-tocopherol, a-tocopherylquinone i.e 50µM and 100µM, an analysis was performed
starting with the 50µM, and then with the 100µM, ensuring the peaks appeared at the same
wavelength, but the absorbance of each concentration had doubled. For analyzing the vaped
DL-a-tocopherol acetate, 500µL of pure ethanol was placed into the quartz cuvette followed
by 500µL of vaped DL-a-tocopherol acetate and mixed several times by gently pipetting
500µL within the quartz cuvette. This initial reading is a 1:2 dilution. After the 1:2 dilution
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analysis was completed, 500µL of the mixed sample within the cuvette was taken out and
placed into a borosilicate tube. Another dilution was done by adding 500µL of pure ethanol to
the 1:2 dilution within the cuvette now making a 1:4 dilution following the same mixing
process previously stated, which was done repeatedly until a 1:64 dilution was achieved.

ANALYSIS OF VAPED VEA MATERIAL WITH HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY
To analyze the DL-a-tocopherol acetate vaped solution, several samples of 500µL
were dried from each of the various collections over two days in the cell culture hood. Then,
1000µL of the prepared mobile phase (97% methanol, 2% acetic acid, and 1% water) was
added to the dried samples, which were then mixed for 30 seconds via finger vortex and then
the 1000µL samples were placed into a 12x32mm amber glass autosampler vial and crimped
with a 11mm aluminum seal (VWR International West Chester, PA). Samples were analyzed
using the Agilent 1200 series diode array and multiple wavelength detector using an injection
1mL/minute, with 20µL per injection, through a Luna 5u C18(2) 100A, 150x4.6mm column
(Phenomenex Torrance, California 90501). The wavelength analysis was set to several
wavelengths: 225nm, 240nm, 250nm, 260nm, 270nm, 280nm, 290nm, 360nm. The
temperature of the sample was at a constant 21-22°C, with the heating plate holding the
column being set to a temperature of 25°C. Samples ran for 20 minutes to achieve peaks of
interest.

TOXICITY ANALYSIS OF VAPED DL-α-TOCOPHEROL ACETATE FRACTIONS
Toxicity of DL-a-tocopherol acetate fractions was assessed by first collecting various
fractions from DL-a-tocopherol acetate solution. To do this, samples of DL-a-tocopherol
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acetate were prepared as described above for HPLC analysis. One hundred µL samples were
injected through the HPLC using the same C18 column mentioned above at rate of
1mL/minute. Separate 1mL fractions (every minute) were collected for a total run time of 20
minutes. All fractions were collected in glass borosilicate tubes numbered 1-20. After
collection, all tubes were placed within a cell culture hood to dry for 48 hours. Once samples
were dried they were resuspended using 100µL of 100% (v/v) pure ethanol. Each fraction
was thoroughly mixed and plated in a 48-well polystyrene cell culture plate (Corning
Incorporated, Corning, NY 14831) then placed in the cell culture hood to dry. Once dried,
100µL of RPMI 1640 cell culture media was added to the wells to resuspend the dried down
DL-a-Tocopherol acetate fractions within each well and gently mixed for 1 minute. THP-1
cells were then plated at 2x104 cells/well and incubated for 24-hours. Following incubation
cell viability and proliferation were measured through the use of a hemocytometer and trypan
blue exclusion assay following the same protocol mentioned above.

GAS CHROMATOGRAPHY MASS SPECTROMETRY ANALYSIS (GCMS)
GCMS was carried out by Dr. Rui Liu at the Centers for Metals in Biology and
Medicine Integrative Molecular Analysis Core in the UNM College of Pharmacy. Vaped DLa-tocopherol acetate samples (1mL) were dried down and resuspending in 1.5mL of ethanol
(100%).

LIQUID CHROMATOGRAPHY MASS SPECTROMETRY ANALYSIS (LCMS)
LCMS analysis was carried out by Dr. Curt Mowry, the Director of the Mass
Spectrometry Facility at the University of New Mexico. Vaped DL-a-tocopherol acetate
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samples (1mL) were dried down over 24-48 hours and resuspended in mobile phase (97%
ethanol, 2%H2O, and 2% acetic acid) up to 1-1.5mL.

STATISTICAL ANALYSIS
Results are expressed as mean ± standard deviation. For statistical significance
between samples, a t-test was used and a two-way ANOVA analysis. MTT viability analysis
was performed using a t-test and is presented as a percent of the VC.
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CHAPTER 3: RESULTS
TOXICITY OF VEA
Toxicity analysis of 25µM VE, VEA, and TQ across six days of treatment revealed
that VE, and VEA had no statistically significant impact on viability or proliferation when
compared to VC (P>0.05) as seen in Figure 4 A and B. However, TQ at 25µM did have a
statistically significant impact on viability on day six and had a significant impact on
proliferation on days five and six compared to all other treatment groups (*P<0.05 by twoway ANOVA; Figure 5A). A dose response of VEA up to 45µM had no significant impact
on viability when compared to VC (P>0.05).
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Figures 5. A) and B) Measure of cell growth and viability using a hemocytometer and trypan
blue exclusion in THP-1 cells treated with VE, VEA, TQ, and VC. C) Dose-Response of
THP-1 cells with VEA with known concentrations analyzed through the use of a MTT assay.
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SPECTROPHOTOMETRIC ANALYSIS
Spectrophotometric analysis of VE at 50µM and 100µM (Figure 6A) showed a
wavelength of 290nm and absorbance values of 0.1 and 0.2, respectively. VEA at 50µM and
100µM (Figure 6B) had a wavelength of 280nm and absorbance of 0.2 and 0.4, respectively.
TQ at 50µM and 100µM (Figure 6C) had a wavelength of 260nm with absorbance values of
1.6 and 3.2, respectively. Lastly, vaped DL-a-tocopherol acetate was analyzed on the
spectrophotometer which revealed a unique peak with a wavelength of 230nm and an
absorbance of 1. A secondary peak was also seen with a wavelength of 280nm and an

Absorbance

Absorbance

absorbance of 0.2 (Figure 6D).
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Absorbance

Absorbance
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Figure 6. Spectrophotometric analysis of VE, VEA, TQ and Vaped DL-a-tocopherol
acetate. A) Absorbance of VE at 50µM (red) and 100µM (green). B) Absorbance of VEA at
50µM (blue) and 100µM (red). C) Absorbance of TQ at 50µM (blue) and 100µM (red). D)
Absorbance of vaped VEA in a 1:128 dilution. The red arrow represents a unique peak found
after multiple dilutions.
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS
HPLC analysis of vaped VEA resulted in multiple UV visible peaks with varying
retention times. The three peaks of which have the highest intensity are the peaks at 1.587
minutes, 7.766 minutes, and 15.588 minutes. The respective areas under the curve (AUC) are
as follows 1007.812 mAU*s, 1300.901 mAU*s, and 2166.953 mAU*s (Figure 6A). Analysis
of VEA at 100µM had a peak retention time of 15.278 minutes and an AUC of
151.647mAU*s (Figure 7B). Figure 6C shows analysis of vaped VEA spiked with 100µM
VEA, which maintained the previous peaks as seen in Figure 6A. However, there was an
increase in intensity of the peak at 15 minutes due to the addition of 100µM VEA as the
AUC increased from 2166.953mAU*s to 2318.314 mAU*s. A standard curve was made
plotting the AUC of VEA to known concentrations (Figure 7D). The linear regression
analysis gave a slope of y=4.397x with an R2 = 0.99; *P<0.001.
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Figure 7. HPLC analysis and Standard Curve: A. HPLC analysis of vaped VEA showing
breakdown of VEA into various byproducts with multiple peaks observed at various retention
times ranging from 1.141-15 minutes. B. HPLC analysis of VEA alone with a known
concentration of 100µM. C. HPLC analysis of vaped VEA spiked with a 100µM VEA
showing the breakdown of VEA into various byproducts with retention times ranging from 115minutes. D. Standard curve formed using the AUC of known VEA concentrations starting
with 100µM followed by 250µM, 500µM, 1000µM and 1500µM.
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Figure 8. A-D. Dose Response to vaped VEA solution showing a dose-response of THP-1
cells using various percent concentrations of vaped VEA solution.

DOSE-RESPONSE OF THP-1 CELLS TO VAPED VEA
THP-1 cell viability was significantly decreased compared to VC when treated with
vaped VEA at the varying percentages as early as one day after exposure from 0.1%-0.5%
(*P < 0.05; Figure 8A-D). 0.4% vaped VEA contains approximately 25µM VEA. A
secondary dose-response was done using a different method for the results from (Figure 9AB). The results of the secondary dose-response revealed that THP-1 viability was
significantly different when compared to both VC and untreated control (UC) after 24 hours
of exposure using 50, 75, and 100µL (*P<0.05). MTT analysis revealed THP-1 viability was
significantly different compared to untreated control (UC) across all exposure groups
including vehicle control (VC). (*P<0.05)
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Figure 9. Dose-Response of THP-1 cells using vaped DL-a-tocopherol acetate solution at
various volumes allowing for the solution of vaped DL-a-tocopherol acetate to dry down
within the wells prior to the addition of cellular media and THP-1 cells. Figure 9A is using
the trypan blue hemocytometry assay and Figure 9B is using the MTT assay.

LC-MS ANALYSIS
Visible peaks are seen at 1.51 minutes with increased concentration compared to the
mobile phase in all three samples - Peak 8, VEA1, and vape 2. VEA1 and Vape 2 show a
secondary peak at 2.80 minutes that is not found within the other samples. The peaks at 2.80
minutes represent VEA (Figure 10A). Upon further analysis of the peak found at
1.51minutes, a higher area under the curve was observed compared to all other peaks within
the sample. The relative measured mass of the peak in Figure 10B was found to be 1193m/z
and when normalized 803.3m/z. Lastly, analysis of the spectrum from the peak at 1.51
minutes gave several readings as seen in Figure 9C. The three peaks with similar MW were
at 413,803, 1193. Sodium was found within each sample in an aggregate contributing to the
increased molecular weight seen at each of the three identified peaks of the spectrum.
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Figure 10. LCMS data analyzing vaped DL-a-tocopherol acetate collections. A) Total ion concentrations of various
samples compared to the mobile phase which is made up of 97% methanol, 2% acetic acid, and 1% water. B)
Represents the mass of the peak found at 1.51 minutes and its relative concentration. C) Represents the spectrum of
the peak found at 1.51 minutes.
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CHAPTER 4: DISCUSSION/FUTURE STUDIES
In this study, we showed that vaped DL-a-tocopherol acetate is toxic to THP-1
monocytic cells, as shown in Figures 7-8, and VEA alone up to 45µM, as seen in Figure 1, is
not cytotoxic to THP-1 monocytic cells. This study also found that VEA was degraded
through the vaping process with the formation of multiple byproducts observed. The
formation of multiple byproducts was seen on the results of the spectrophotometric, HPLC,
and LCMS analysis from Figures 5, 6 and 9 as compared to controls of using VEA alone and
mobile phase. A unique peak was observed throughout each step of the analysis found at 7-8
minutes through HPLC, and at 1.5 minutes through GCMS. Spectrophotometric analysis
showed a unique peak with an absorbance of 230nm. VEA has also found in each step of the
analysis after being vaped.
The results of this study further support that VEA alone, even at high concentrations
of 45µM, is not cytotoxic compared to the study done by Matsumoto et al. (2020), that
reported the toxicity of vaped VEA is dose-dependent, based on their cell culture model
using human AT II cells as they saw a decrease in viability with increased exposure to vaped
VEA9. Not only was VEA not cytotoxic to THP-1 monocytic cells, estimation analysis using
the developed standard curve showed that after the addition of vaped VEA in cell culture,
THP-1 cells were exposed to ~25µM VEA, which is the concentration found at normal
physiological levels. Although, VEA alone has not been shown to be cytotoxic, the
byproducts formed from vaping VEA showed a different outcome. Other studies have
reported that VEA is broken down into various byproducts; however, of the compounds that
have been reported within the various studies, none of these studies have reported a molecule
with the same MW found in my research, with a MW=390. For example, a study done by
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Wu, Dan et al. (2020) reported the formation of ketene (MW=42.04); however, within this
study, no ketene formation was seen upon analysis. Ketene itself is a highly reactive
molecule that is consumed just as quickly as it is formed suggesting that although ketene has
the potential to be formed an individual would likely experience severe irritation upon
inhalation of ketene28. Other reported compounds from various studies have reported
acetone, 3,7,11-trimethyl-1-dodecanol, 1-pristene, and various quinone structures, such as
durohydroquinone, durohydroquinone monoacetate, and methyl octadecenoate3,6,7,10,11. Of the
reported compounds, none have been characterized with the same MW=390 found in this
study. It should be mentioned that although various quinone structures have been reported,
the quinones associated with toxicity are those that are less substituted, as found by Wang et
al. (2006). Wang et al. (2006) reported a significant decrease in cell viability when
comparing g-TQ to a-TQ with g-TQ having a significant impact on viability. The toxicity of
g-TQ was attributed to the difference in the substitution of the chromanol ring compared to
a-TQ, allowing for g-TQ to undergo Michael addition reactions due to one unsubstituted
carbon5. This study showed toxicity with TQ, a potential oxidation product of VEA, after 6
days of exposure and an inhibition of cell growth as soon as 4 days shown in Figure 1;
however, through HPLC analysis and spectrophotometric analysis, TQ formation was not
observed in vaped VEA.
The current literature is limited when it comes to the toxicity of vaping VEA, and,
although the study done by Blount et al. (2020) reported that VEA may be a causative agent
in causing EVALI, further studies are needed to identify other potential toxicants that may be
formed through the vaping of VEA. This study demonstrated the breakdown of VEA through
vaping, and toxicity of vaped VEA in cell culture. However, further studies are needed for
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the characterization of the unique peak observed with a MW of 390. H1NMR would
characterize the molecular structure of the molecule with a MW of 390 and potential
mechanistic properties that toxicity may occur. Other toxicants may be present that are not
seen within the current analysis as they may not be detectable through UV warranting further
characterization. Because ketene was reported previously and not found within this current
study, or within the study done by Canchola et. al. (2021), which analyzed vaped DL-atocopherol acetate byproducts formed through vaping at various temperatures, alternative
capture methods should be considered43. The way in which oral VEA and vaped DL-atocopherol acetate are absorbed may give an indication to toxicity. Oral administration of
VEA through the gastrointestinal tract is taken up by scavenger receptor class B proteins type
I (SR-BI) and intracellular cholesterol transporter 1 (NPC1L1)44. Comparatively, there is no
data to suggest how VEA may be absorbed or eliminated from the pulmonary system.
Further analysis in mice models may suggest potential cellular pathways that may be
impacted through inhalation of VEA. The overall contribution of this work has shown that
VEA alone is not toxic to THP-1monocytic cells; but vaped VEA is toxic, and vaping VEA
results in the breakdown of VEA into various byproducts including a unique molecule with a
MW of 390.
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